Which Patients With Hepatitis B Should We Be Treating?

Are we treating HBV early enough? Is it time to move the goalposts regarding the timing of treatment initiation? What are the potential benefits of earlier treatment?

To answer these questions, Ira M. Jacobson, MD, leads a panel discussion with Tatyana Kushner, MD, MSCE, and Paul Y. Kwo, MD, exploring which patients with HBV we should be treating, including a focus on:

• Guideline-based treatment recommendations and their limitations
• Data describing the relationship between viral suppression and HBV DNA integration
• More expansive indications for HBV treatment based on virologic considerations

Presenters:

Ira M. Jacobson, MD
Professor of Medicine
Director of Hepatology
NYU Langone Health
New York, New York

Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at 
Mount Sinai
New York, New York

Paul Y. Kwo, MD
Professor of Medicine 
Director of Hepatology 
Stanford University School of Medicine
Palo Alto, California

Link to the full program: https://bit.ly/3R1PMi4

Link to the slides: https://bit.ly/3N5Fpsm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.